MX2009006528A - Sal de succinato de la 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol- 3-il)fenoxi)metil)quinolina. - Google Patents

Sal de succinato de la 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol- 3-il)fenoxi)metil)quinolina.

Info

Publication number
MX2009006528A
MX2009006528A MX2009006528A MX2009006528A MX2009006528A MX 2009006528 A MX2009006528 A MX 2009006528A MX 2009006528 A MX2009006528 A MX 2009006528A MX 2009006528 A MX2009006528 A MX 2009006528A MX 2009006528 A MX2009006528 A MX 2009006528A
Authority
MX
Mexico
Prior art keywords
methyl
succinate salt
pyrazol
pyridin
quinoline
Prior art date
Application number
MX2009006528A
Other languages
English (en)
Inventor
Patrick Robert Vorhoest
Caroline Proulx
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39321475&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009006528(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MX2009006528A publication Critical patent/MX2009006528A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a una sal de succinato de la 2-((4-(1-metil-4- (piridin-4-il)-1 H-pirazol-3-il)fenoxi)metil)qui nolina, y a un método para tratar trastornos del Sistema Nervioso Central (SNC) y otros trastornos en un mamífero, que incluye a un ser humano, administrando al mamífero la sal de succinato. "También" se refiere a composiciones farmacéuticas que contienen un vehículo farmacéuticamente aceptable y la sal de succinato.
MX2009006528A 2006-12-21 2007-12-03 Sal de succinato de la 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol- 3-il)fenoxi)metil)quinolina. MX2009006528A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87126006P 2006-12-21 2006-12-21
PCT/IB2007/003819 WO2008084299A1 (en) 2006-12-21 2007-12-03 Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline

Publications (1)

Publication Number Publication Date
MX2009006528A true MX2009006528A (es) 2009-06-26

Family

ID=39321475

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006528A MX2009006528A (es) 2006-12-21 2007-12-03 Sal de succinato de la 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol- 3-il)fenoxi)metil)quinolina.

Country Status (25)

Country Link
US (1) US8283471B2 (es)
EP (1) EP2125786B1 (es)
JP (1) JP5254602B2 (es)
KR (2) KR20120043775A (es)
CN (1) CN101611029B (es)
AR (1) AR064417A1 (es)
AT (1) ATE502028T1 (es)
AU (1) AU2007343135B2 (es)
BR (1) BRPI0720936A2 (es)
CA (1) CA2673435C (es)
CY (1) CY1111919T1 (es)
DE (1) DE602007013294D1 (es)
DK (1) DK2125786T3 (es)
ES (1) ES2360014T3 (es)
HK (1) HK1134670A1 (es)
IL (1) IL199389A (es)
MX (1) MX2009006528A (es)
NZ (1) NZ577716A (es)
PL (1) PL2125786T3 (es)
PT (1) PT2125786E (es)
RU (1) RU2430918C2 (es)
SI (1) SI2125786T1 (es)
TW (1) TWI359660B (es)
WO (1) WO2008084299A1 (es)
ZA (1) ZA200904230B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
US20120214842A1 (en) * 2011-02-18 2012-08-23 Exonhit Therapeutics Sa Methods for treating diseases of the retina
WO2014142322A1 (ja) 2013-03-15 2014-09-18 第一三共株式会社 ベンゾチオフェン誘導体
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
KR102233916B1 (ko) * 2019-05-28 2021-03-30 주식회사 엘지생활건강 Pq1 숙신산을 포함하는 피부 보습, 주름 개선 및 탄력 증진용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
DK1360169T3 (da) * 2001-02-12 2007-11-26 Wyeth Corp Succinatsalt af O-desmethyl-venlafaxin
AU2002341327A1 (en) * 2001-11-29 2003-06-10 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
PL370858A1 (en) * 2001-12-12 2005-05-30 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production
US7772240B2 (en) * 2003-08-18 2010-08-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
NZ555737A (en) * 2005-01-07 2010-01-29 Pfizer Prod Inc Heteroaromatic quinoline compounds and their use as PDE10 inhibitors
WO2006078828A2 (en) 2005-01-21 2006-07-27 Cabot Corporation Method of making nanoparticulates and use of the nanoparticulates to make products using a flame reactor
TW200730530A (en) * 2005-12-16 2007-08-16 Wyeth Corp Lyophilized compositions of a triazolopyrimidine compound

Also Published As

Publication number Publication date
CA2673435A1 (en) 2008-07-17
AU2007343135B2 (en) 2013-03-21
RU2009123347A (ru) 2011-01-27
IL199389A (en) 2014-01-30
KR20090092338A (ko) 2009-08-31
PT2125786E (pt) 2011-04-21
CY1111919T1 (el) 2015-11-04
EP2125786B1 (en) 2011-03-16
PL2125786T3 (pl) 2011-07-29
CN101611029A (zh) 2009-12-23
US8283471B2 (en) 2012-10-09
CN101611029B (zh) 2014-09-10
NZ577716A (en) 2012-10-26
JP2008208114A (ja) 2008-09-11
DK2125786T3 (da) 2011-05-09
SI2125786T1 (sl) 2011-05-31
TWI359660B (en) 2012-03-11
WO2008084299A1 (en) 2008-07-17
DE602007013294D1 (de) 2011-04-28
BRPI0720936A2 (pt) 2014-03-11
HK1134670A1 (en) 2010-05-07
ATE502028T1 (de) 2011-04-15
ES2360014T3 (es) 2011-05-31
US20100063089A1 (en) 2010-03-11
TW200833337A (en) 2008-08-16
KR20120043775A (ko) 2012-05-04
JP5254602B2 (ja) 2013-08-07
RU2430918C2 (ru) 2011-10-10
ZA200904230B (en) 2010-04-28
EP2125786A1 (en) 2009-12-02
AR064417A1 (es) 2009-04-01
CA2673435C (en) 2012-10-09
AU2007343135A1 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
IL186412A0 (en) Dihydropyridine compounds and compositions for headaches
TW200616953A (en) Indole, indazole or indoline derivatives
MX2010006238A (es) Formulaciones del acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5 -il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico.
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
NO341523B1 (no) Benzoimidazol-2-ylpyrimidiner og -pyraziner som modulatorer av histamin H4-reseptoren, farmasøytisk sammensetning samt anvendelse
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
MX2009006528A (es) Sal de succinato de la 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol- 3-il)fenoxi)metil)quinolina.
TW200631956A (en) Azabenzoxazoles for the treatment of CNS disorders
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
MX368157B (es) Formulaciones de sal de meglumina del acido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxilico.
WO2009038385A3 (en) Novel compounds having indazole frameworks, methods for preparing the same and pharmaceutical composition comprising the same
SI1853232T1 (sl) Stabilna kristalna oblika bifeprunoks-mezilata, njegove dozirne oblike in postopki za njihovo uporabo
UA98772C2 (ru) Производные циклопропиламина как модуляторы н3-гистаминового рецептора
TW200732304A (en) Piperidine derivatives
WO2009145590A3 (en) Phenyl piperazine compounds, pharmaceutical composition comprising the same, and use thereof
MX2015003732A (es) Tratamiento de enfermedad de alzheimer leve y moderada.
WO2008014247A3 (en) 4 -arylalkoxymethyl-4- phenyl piperidines and their use as neurokinin receptor antagonists for the treatment of cns disorders
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
TW200628476A (en) Azabenzoxazoles for the treatment of CNS disorders
UA86051C2 (en) Substituted quinoline compounds
MX2009005738A (es) Derivado piperidinico utilizado para tratar enfermedades mediadas por el receptor 5 de quimiocina.
MX2007005824A (es) Agonistas y antagonistas del receptor de somatostatina.
WO2006051413A8 (en) Azabenoxazoles for the treatment of cns disorders

Legal Events

Date Code Title Description
FG Grant or registration